Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Beckingsale T, Gerrand C. (i) Osteosarcoma. Orthopaedics and Trauma 2010, 24(5), 321-331.
• Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research 2010, 70(15), 6268-6276.
• Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, Edmondson RJ, Darby S, Berchuck A, Laird P, Pearce CL, Ramus SJ, Jacobs IJ, Gayther SA. Microcell mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia 2010, 12(7), 579-589.
• Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. International Journal of Oncology 2010, 37(2), 367-376.
• Culpin RE, Anderson JJ, Angus B, Proctor SJ, Crosier S, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. In: EJC Supplements: 21st Meeting of the European Association for Cancer Research. 2010, Oslo, Norway: Pergamon.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, FL: Blood: American Society of Hematology.
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• McWeeney S, Pemberton L, Loriaux M, Vartanian K, Willis S, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker B, Snead J, MacPartlin M, O'Brien S, Melo J, Lange T, Harrington C, Deininger M. A gene expression signature of CD34⁺ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115(2), 315-325.
• Trempe JF, Brown NR, Noble MEM, Endicott JA. A new crystal form of Lys48-linked diubiquitin. Acta Crystallographica. Section F: Structural Biology and Crystallization Communications 2010, 66(9), 994-998.
• Chapiro E, Russell LJ, Struski S, Cave H, Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA, Harrison CJ, Nguyen-Khac F. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010, 24(7), 1362-1364.
• Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. British Journal of Haematology 2010, 150(3), 371-373.
• Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010, 115(2), 206-214.
• Chapiro E, Russell L, Lainey E, Kaltenbach S, Ragu C, Della-Valle V, Hanssens K, Macintyre EA, Radford-Weiss I, Delabesse E, Cave H, Mercher T, Harrison CJ, Nguyen-Khac F, Dubreuil P, Bernard OA. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24(3), 642-645.
• Podesta JE, Griffin MJ, Sugar R, Squires MS, Boddy A, Linardopoulos S, Pearson ADJ, Moore AS. Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. Age- and sex-adjusted incidence rates of adults with acute lymphoblastic leukemia (ALL) in the northern part of England Response. Blood 2010, 116(6), 1012-1012.
• Peasland A, Matheson E, Hall A, Irving J. Alternative splicing of hMLH1 in childhood acute lymphoblastic leukaemia and characterisation of the variably expressed Δ9/10 isoform as a dominant negative species. Leukemia Research 2010, 34(3), 322-327.
• Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Cancer Research 2010, 70(10), 3985-3995.
• National Confidential Enquiry into Patient Outcome and Death. An age old problem. London: NCEPOD, 2010.
• Jiang XY, Grant H, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, Brien SO, Khorashad JS, Gerrard G, Wang LH, Irving J, Wang M, Karran L, Dyer MJS, Forrest DL, Page K, Eaves CJ, Woolfson A. Analysis of BCR ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype. In: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, FL: Blood: American Society of Hematology.
• Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JAE, Wang M, Karran L, Dyer MJS, Forrest D, Page K, Eaves CJ, Woolfson A. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia 2010, 24(10), 1817-1821.
• Jiang XY, Grant H, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang LH, Irving J, Wang M, Karran L, Dyer MJS, Forrest DL, Page K, Eaves CJ, Woolfson A. Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Garrido Castro P, Bomken S, Seslija L, Stam R, Latif ES, Batey MA, McNeill H, Pieters R, Vormoor J, Greil J, Heidenreich O. ANGIOPOIETIN1 a Novel Factor Implicated In MLL Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene Dependent Manner. In: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, FL: Blood: American Society of Hematology.
• Castro PG, Bemken S, Seslija L, Stam R, Latif ES, Batey MA, McNeill H, Pieters R, Vormoor J, Greil J, Heidenreich O. ANGIOPOIETIN1-a Novel Factor Implicated In MLL-Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene-Dependent Manner. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• San-Hoo S, Warburton KG, Robson CN, Edmondson RJ. Anti androgen therapy in ovarian cancer: an overlooked treatment modality?. The European Journal of Clinical & Medical Oncology 2010, 2(3), 39-43.
• Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, Fielding AK, Foroni L. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study. British Journal of Haematology 2010, 148(3), 394-401.
• Willmore E, Skowronska A, Mulligan EA, Ahmed G, Elliott S, Summerfield GP, Hamlen K, Lowe C, Durkacz BW, Stankovic T. ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Cano C, Golding BT, Haggerty K, Hardcastle IR, Peacock M, Griffin RJ. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK). Organic & Biomolecular Chemistry 2010, 8(8), 1922-1928.
• Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, Bénard J, Oumata N, Galons H, Meijer L. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes & Cancer 2010, 1(4), 369-380.
• Nannizi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, Ottley CJ, Del Tacca M, Danesi R. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemotherapy and Pharmacology 2010, 66(3), 547-558.
• Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine Is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia. In: Blood: American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
• Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010, 103(10), 1588-1596.
• Dickinson A, Pearce K, Jackson G, Collin M, Norden J, Holler E, Greinix H, Bickeboller H, Balvarca Y, Rocha V, Kolb H, Hromadnikova I, Sedlacek P, Gratwohl A. Clinical and genetic risk assessment for overall survival in haematopoietic stem cell transplantation. In: 36th Annual Meeting of the European Group for Blood and Marrow Transplantat/9th Meeting of the EBMT Data Management Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Quality Management Meeting. 2010, Vienna, Austria: Bone Marrow Transplantation, Nature Publishing Group.
• Coenen EA, Raimondi SC, Harbott J, Martin Z, Balgobind BV, Alonzo TA, Auvrignon A, Beverloo B, Chang MR, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz J, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, Eibrink MV. Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL Rearranged AML Results from an International Retrospective Study. In: Blood: 42nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. Journal of Clinical Oncology 2010, 28(32), 4790-4799.
• Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics 2010, 42(2), 132-136.
• Paleri V, Wight R, Silver C, Haigentz M, Takes R, Bradley P, Rinaldo A, Sanabria A, Bień S, Ferlito A. Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice. Oral Oncology 2010, 46(10), 712-719.
• Thornhill A, Gordon A, Taylor J, Bennett K, Emmerson C, Grigorova M, Gabriel A, Atalla N, Menabawey M, Griffin D, Handyside A. Comparative genomic hybridisation (aCGH) to identify unbalanced products associated with specific chromosomal rearrangements. In: 10th International Congress on Preimplantation Genetic Diagnosis. 2010, Montpellier: Elsevier.
• Rostron AJ, Cork DMW, Avlonitis VS, Fisher AJ, Dark JH, Kirby JA. Contribution of Toll-Like Receptor Activation to Lung Damage After Donor Brain Death. Transplantation 2010, 90(7), 732-739.
• Britton KM, Harvey IJ, Stemke-Hale K, Lennard TWJ, Meeson AP. Could side population cells be an indicator of progression to hormone nonresponsive breast cancer. In: Breast Cancer Research: Conference on Breast Cancer Research. 2010, London, UK: Current Medicine Group Ltd.
• Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary SE, White E, Eden C, Hogg T, Northcott P, Mack S, Neale G, Wang YD, Coyle B, Atkinson J, Dewire M, Kranenburg TA, Gillespie Y, Allen JC, Merchant T, Boop FA, Sanford RA, Gajjar A, Ellison DW, Taylor MD, Grundy RG, Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010, 466(7306), 632-636.
• Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DKH, Wheatley K, de Graaf SSN, van den Berg E, Burnett AK, Gibson BES. Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. Journal of Clinical Oncology 2010, 28(16), 2674-2681.
• Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C. Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia 2010, 24(5), 1080-1084.
• Meschini E, Endicott JA, Golding BT, Hardcastle IR, Newell DR, Noble MEM, Wang LZ, Griffin RJ. Design and synthesis of dual CDK2 and CDK7 inhibitors. In: Abstracts of Papers of the American Chemical Society. 2010, American Chemical Society.
• Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clinical Cancer Research 2010, 16(8), 2344-2351.
• Clapham KM, Rennison T, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Golding BT, Hardcastle IR, Newell DR, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• McCracken S, Durkan G, Pickard R, Robson C. Diagnosis and management of prostate cancer in the older man. Reviews in Clinical Gerontology 2010, 20(3), 193-204.
• Banerji S, Hide BRS, James JR, Noble MEM, Jackson DG. Distinctive Properties of the Hyaluronan-binding Domain in the Lymphatic Endothelial Receptor Lyve-1 and Their Implications for Receptor Function. Journal of Biological Chemistry 2010, 285(14), 10724-10735.
• Strathdee G, Ferguson S, Sim A, Brown R. DNA methylation does not regulate JUNB expression in CML: Comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al. [Leuk. Res. 33 (2009) 1361-1366]. Leukemia Research 2010, 34(5), 685-686.
• Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
• Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, Robson CN, Kozielski F, Leung HY. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Molecular Cancer Therapeutics 2010, 9(6), 1730-1739.
• Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, Kronnie GT, Bourquin JP, Domany E, Izraeli S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115(5), 1006-1017.
• Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
• Sinclair PB, Bian Q, Plutz M, Heard E, Belmont AS. Dynamic plasticity of large -scale chromatin structure revealed by self-assembly of engineered chromosome regions. Journal of Cell Biology 2010, 190(5), 761-776.
• Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Revesz T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010, 376(9757), 2009-2017.
• Plummer R. Encouraging first experiences with PARP inhibitors. In: Annals of Oncology: 35th European Society for Medical Oncology (ESMO) Congress. 2010, Milan, Italy: Oxford University Press.
• Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ. Evaluation of Multiplex Ligation-Dependent Probe Amplification as a Method for the Detection of Copy Number Abnormalities in B-Cell Precursor Acute Lymphoblastic Leukemia. Genes, Chromosomes & Cancer 2010, 49(12), 1104-1113.
• Paleri V, Staines K, Sloan P, Douglas A, Wilson J. Evaluation of oral ulceration in primary care. British Medical Journal 2010, 340, c2639.
• Razak AA, Nutt J, O'Toole K, Black F, Cole M, Plummer R, Lunec J, Calvert H. Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy. In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Handyside A, Grifo J, Gabriel A, Thornhill A, Griffin D, Ketterson K, Prates R, Tormasi S, Fischer J, Munné S. First clinical application of karyomapping for PGD of Gaucher disease combined with 24 chromosome screening. In: 10th International Congress on Preimplantation Genetic Diagnosis. 2010, Montpellier: Elsevier.
• Oozeer NB, Owen S, Perez BZ, Jones G, Welch AR, Paleri V. Functional status after total laryngectomy: cross-sectional survey of 79 laryngectomees using the Performance Status Scale for Head and Neck Cancer. Journal of Laryngology and Otology 2010, 124(4), 412-416.
• Williamson D, Missiaglia E, deReynies A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M, Freneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O. Fusion Gene-Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology 2010, 28(13), 2151-2158.
• Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, Smith MT, Allan JM, Taylor GM, United Kingdom Childhood Cancer Study. Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood 2010, 115(19), 3923-3929.
• Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS. Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood 2010, 115(22), 4472-4477.
• Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ. Glomerular Toxicity Persists 10 Years After Ifosfamide Treatment in Childhood and Is Not Predictable by Age or Dose. Pediatric Blood & Cancer 2010, 54(7), 983-989.
• Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer 2010, 102(11), 1555-1577.
• Baumli S, Endicott JA, Johnson LN. Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB. Chemistry & Biology 2010, 17(9), 931-936.
• Mehanna H, Paleri V, West C, Nutting C. Head and neck cancer - Part 1: Epidemiology, presentation, and prevention. BMJ 2010, 341(7774), 663-666.
• Mehanna H, West C, Nutting C, Paleri V. Head and neck cancer - Part 2: Treatment and prognostic factors. BMJ 2010, 341(7775), 721-725.
• Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NV, Boos J, Kohler G, Leuschner I, Pearson ADJ, Lunec J, Tweddle DA. High frequency of p53/MDM2/p14^ARF pathway abnormalities in relapsed neuroblastoma. Clinical Cancer Research 2010, 16(4), 1108-1118.
• Fielding AK, Buck G, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Tallman MS, Rowe JM, Goldstone AH. Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Fielding AK, Buck G, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Tallman MS, Rowe JM, Goldstone AH. Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
• Rehe K, Wilson K, Bomken S, McNeill H, Stanulla M, Den Boer ML, Irving J, Heidenreich O, Vormoor J. In Acute Lymphoblastic Leukaemia, Stemness Is Frequent and Ubiquitous. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Rehe K, Wilson K, Bomken S, McNeill H, Stanulla M, Den Boer ML, Irving J, Heidenreich O, Vormoor J. In Acute Lymphoblastic Leukaemia, Sternness Is Frequent and Ubiquitous. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Mathers J, Strathdee G, Relton C. Induction of Epigenetic Alterations by Dietary and Other Environmental Factors. In: Herceg, Z., Ushijima, T, ed. Advances in Genetics: Epigenetics and Cancer, Part B. Amsterdam; London: Academic Press, 2010, pp.4-39.
• Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Cancer 2010, 102(6), 1003-1009.
• Binda O. InhibitING entry into S phase and cell cycle progression. Cell Cycle 2010, 9(20), 4043-4051.
• Belmont AS, Hu Y, Sinclair PB, Wu W, Bian Q, Kireev I. Insights into interphase large-scale chromatin structure from analysis of engineered chromosome regions. Cold Spring Harbor Symposia on Quantitative Biology 2010, 75, 453-460.
• Gabriel IH, Marin D, Ahmad S, Foroni L, de Lavallade H, Clark RE, O'Brien S, Sergeant R, Milojkovic D, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. In: Blood: American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
• Gessner A, Thomas M, Garrido Castro P, Büchler L, Scholz A, Brümmendorf TH, Martinez Soria N, Vormoor J, Greil J, Heidenreich O. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010, 24(10), 1751-1759.
• Edmondson RJ, Errington CA, Mansour DJA. Liquid based cytology improves the positive predictive value of glandular smears compared to conventional cytology. European Journal of Gynecological Oncology 2010, 31, 288-290.
• Bechmann LP, Vetter D, Hannivoort RA, Patman G, Lee UE, Fiel MI, Agius L, Reeves H, Friedman SL. Liver-specific deletion of KLF6 uncovers novel transcriptional pathways linked to lipid and glucose homeostasis. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
• Israels T, Damen CWN, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer 2010, 46(10), 1841-1847.
• Payne SL, Rodriguez-Aristegui S, Bardos J, Cano C, Golding BT, Hardcastle IR, Peacock M, Parveen N, Griffin RJ. Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors. Bioorganic & Medicinal Chemistry Letters 2010, 20(12), 3649-3653.
• Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Fowler TM. Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology (ASH). 2010, Orlando, Florida, USA: American Society of Hematology.
• Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Mainou-Fowler T. Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Kane EV, Painter D, Roman E, Allan J, Law G, Lightfoot T. Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. Cancer Epidemiology 2010, 34(2), 136-141.
• Hosking FJ, Leslie S, Dilthey A, Moutsianas L, Wang Y, Dobbins SE, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Taylor M, Greaves M, McVean G, Houlston RS. MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2010, 117(5), 1633-1640.
• Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, Gerrard G, Moorman AV, Duke V, Hoffbrand AV, Fielding AK, Goldstone AH, Foroni L. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology 2010, 148(1), 80-89.
• Best A, Matheson E, Minto L, Hall AG, Irving JAE. Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia. Leukemia Research 2010, 34(8), 1098-1102.
• Masurekar AN, Parker CA, Choudhuri S, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Goulden N, Green N, Revesz T, Hoogerbrugge P, Darbyshire P, Love S, Saha V. Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Hayden JT, Allen M, Ryan SL, Nicholson SL, Schwalbe EC, Lusher ME, Lindsey JC, Hauser P, Hasselblatt M, Fruhwald MC, Bailey S, Clifford SC. Molecular Mechanisms in Supratentorial CNS-PNET development. In: Neuro-Oncology: 14th International Symposium on Pediatric Neuro-Oncology. 2010, Vienna, Austria: Oxford University Press.
• Kiwerska K, Rydzanicz M, Kram A, Pastok MW, Antkowiak A, Domagala W, Szyfter K. Mutational analysis of CDKN2A gene in a group of 390 larynx cancer patients. Molecular Biology Reports 2010, 37(1), 325-332.
• Tatevossian RG, Tang B, Dalton J, Forshew T, Lawson AR, Ma J, Neale G, Shurtleff SA, Bailey S, Gajjar A, Baker SJ, Sheer D, Ellison DW. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathologica 2010, 120(6), 679-683.
• Bell E, Chen LD, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Letters 2010, 293(2), 144-157.
• Lee JS, Kim Y, Kim IS, Kim B, Choi HJ, Lee JM, Shin HJ, Kim JH, Kim JY, Seo SB, Lee H, Binda O, Gozani O, Semenza GL, Kim M, Kim KI, Hwang D, Baek SH. Negative regulation of hypoxic responses via induced Reptin methylation. Molecular Cell 2010, 39(1), 71-85.
• Skinner R. Nephrotoxicity of cancer treatment in children. Pediatric Health 2010, 4(5), 519-538.
• Nicholson L, Hall AG, Redfern CP, Irving J. NF kappa B modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia. Leukemia Research 2010, 34(10), 1366-1373.
• Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma. British Journal of Haematology 2010, 149(2), 258-262.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Drayson MT, Ashcroft J, Owen RG, Cook G, Ross FM, Jackson GH, Russell NH, Child JA. Optimising Bone Disease In Myeloma, Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints Results of the MRC Myeloma IX Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Lrrzow MR, Buck G, Dewald G, Fielding A, Ketterling R, Lazarus HM, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Hori S, Jabbar T, Kachroo N, Vasconcelos J, Robson C, Gnanapragasam V. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. Journal of Cancer Research and Clinical Oncology 2010, 137(2), 235-241.
• Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: New therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism and Toxicology 2010, 6(8), 919-938.
• Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Research 2010, 70(4), 1377-1388.
• Lee JH, Jung C, Javadian-Elyaderani P, Schweyer S, Schutte D, Shoukier M, Karimi-Busheri F, Weinfeld M, Rasouli-Nia A, Hengstler JG, Mantilla A, Soleimanpour-Lichaei HR, Engel W, Robson CN, Nayernia K. Pathways of Proliferation and Antiapoptosis Driven in Breast Cancer Stem Cells by Stem Cell Protein Piwil2. Cancer Research 2010, 70(11), 4569-4579.
• Veal GJ, Cole M, Errington J, Pearson ADJ, Gerrard M, Whyman G, Ellershaw C, Boddy AV. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemotherapy and Pharmacology 2010, 65(6), 1057-1066.
• Heer R, Clarke N, Rigas AC, Cheek TR, Pickard R, Leung HY. Phenotypic Modulation of Human Urinary Tract Stroma-derived Fibroblasts by Transforming Growth Factor beta 3. Urology 2010, 76(2), 509.e13-509.e20.
• Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010, 13(4), 337-347.
• Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. British Journal of Cancer 2010, 102(2), 342-350.
• Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncology 2010, 11(5), 429-438.
• Werth D, Grassi G, Konjer N, Dapas B, Farra R, Giansante C, Kandolf R, Guarnieri G, Nordheim A, Heidenreich O. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. European Journal of Cell Biology 2010, 89(2-3), 216-224.
• Moor JW, Patterson J, Kelly C, Paleri V. Prophylactic Gastrostomy before Chemoradiation in Advanced Head and Neck Cancer: a Multiprofessional Web-based Survey to Identify Current Practice and to Analyse Decision Making. Clinical Oncology 2010, 22(3), 192-198.
• McLarnon C, Kulloo P, Mehanna H, Kelly C, Paleri V. Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer. Expert Review of Anticancer Therapy 2010, 10(3), 345-352.
• Echalier A, Endicott JA, Noble MEM. Recent developments in cyclin-dependent kinase biochemical and structural studies. In: BBA - Proteins and Proteomics: 6th International Conference on Inhibitors of Protein Kinases (IPK). 2010, Warsaw, Poland: Elsevier BV.
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. In: 50th Annual Scientific Meeting of the British Society for Haematology. 2010, Edinburgh, Scotland: British Journal of Haematology, Wiley-Blackwell Publishing.
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, and on behalf of the National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3), 354-365.
• Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CPF. Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells. Journal of Biological Chemistry 2010, 285(9), 6091-6100.
• Mulligan EA, Hunter JE, Baird AEG, Elliott S, Summerfield GP, Hamlen K, Lowe C, Wallis J, Veuger S, Durkacz BW, Willmore E. Relationships Between Aberrant Activity of the NF-kappa B Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Rowbotham SE, Boddy AV, Redfern CPF, Veal GJ, Daly AK. Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metabolism and Disposition 2010, 38(8), 1261-1266.
• Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O. Reply to J.R. Anderson et al. Journal of Clinical Oncology 2010, 28(29), e589-e590.
• Sunter NJ, Cowell IG, Willmore E, Watters GP, Austin CA. Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide. Journal of Nucleic Acids 2010, 710589.
• Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metabolism and Disposition 2010, 38(7), 1211-1217.
• Vormoor B, Foy KE, Curtin N, Clifford SC. Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC). In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Abuhammad AM, Lowe ED, Fullam E, Noble M, Schweichler J, Garman EF, Sim E. Structural Studies on the Mycobacterial Arylamine N-Acetyltransferases. In: Drug Metabolism Reviews: 9th International Meeting of the International Society for the Study of Xenobiotics(ISSX). 2010, Istanbul, Turkey: Informa Healthcare.
• Riedinger C, Boehringer J, Trempe JF, Lowe ED, Brown NR, Gehring K, Noble MEM, Gordon C, Endicott JA. Structure of Rpn10 and Its Interactions with Polyubiquitin Chains and the Proteasome Subunit Rpn12. Journal of Biological Chemistry 2010, 285(44), 33992-34003.
• Carbain B, Roche C, Endicott JA, Golding BT, Hardcastle IR, Cano C, Zhen-Wang L, Newell DR, Noble MEM, Griffin RJ. Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors. In: European Journal of Cancer Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin: Elsevier.
• Gibson P, Tong YA, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei YX, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468(7327), 1095-1099.
• Ythier D, Larrieu D, Binet R, Binda O, Brambilla C, Gazzeri S, Pedeux R. Sumoylation of ING2 regulates the transcription mediated by Sin3A. Oncogene 2010, 29(44), 5946-5956.
• Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR. Synthesis and biological evaluation of 5-substituted O-4-alkylpyrimidines as CDK2 inhibitors. Organic & Biomolecular Chemistry 2010, 8(10), 2397-2407.
• Wong C, Griffin RJ, Hardcastle IR, Northen JS, Wang LZ, Golding BT. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated S(N)2 reactivity of 2,2,2-trifluoroethoxysulfonates. Organic & Biomolecular Chemistry 2010, 8(10), 2457-2464.
• Cornell L, Munck JM, Budhisetiawan F, Newell DR, Bardos JI, Manas D, Curtin NJ, Reeves H. Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
• Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, Redfern CPF, Fulda S, Armstrong JL, Lovat PE. Targeting X-Linked Inhibitor of Apoptosis Protein to Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. Journal of Investigative Dermatology 2010, 130(9), 2250-2258.
• Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TOB, Parker C, Vora A, Richards S, Saha V. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia 2010, 24(2), 450-459.
• Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular Cancer Survivorship: Research Strategies and Recommendations. Journal of the National Cancer Institute 2010, 102(15), 1114-1130.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Drayson MT, Owen RG, Cook G, Ross FM, Jackson GH, Child JA. Thalidomide Maintenance Significantly Improves Progression Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used MRC Myeloma IX Results. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Lopez-Lazaro M, Willmore E, Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis 2010, 696(1), 41-47.
• Cresti N, Jamieson D. The pharmacology of trastuzumab and its use in breast cancer. Clinical Medicine Reviews in Oncology 2010, 2, 149-165.
• Nutt JE, Razak ARA, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J. The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. British Journal of Cancer 2010, 102(3), 553-560.
• Forster VJ, Allan JM, Heidenreich O. The t(8,21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Forster VJ, Allan JM, Heidenreich O. The t(8;21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia. In: Blood: American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
• da Silva Dantas A, Patterson MJ, Smith DA, MacCallum DM, Erwig LP, Morgan BA, Quinn J. Thioredoxin regulates multiple hydrogen peroxide-induced signaling pathways in Candida albicans. Molecular and Cellular Biology 2010, 30(19), 4550-4563.
• Binda O, LeRoy G, Bua DJ, Garcia BA, Gozani O, Richard S. Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics 2010, 5(8), 767-775.
• Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. British Journal of Cancer 2010, 103(4), 439-445.
• Paleri V, Patterson J. Use of gastrostomy in head and neck cancer: a systematic review to identify areas for future research. Clinical Otolaryngology 2010, 35(3), 177-189.
• Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, Pepper C, Fegan C, Hall AG, Deignan L, Bacon CM, Pointon JC, Houlston RS, Broderick P, Mainou-Fowler T, Jackson GH, Summerfield G, Evans PA, Strefford JC, Parker A, Oscier D, Pratt G, Allsup DJ. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia 2010, 24(4), 877-881.
• Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Neira AG, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genetics 2010, 42(6), 492-494.